| Host |
Monospecific Mouse |
| Clone |
ZM55 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Breast tissue. |
| Dilution |
- |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant human p75 NGFR protein fragment (around aa 281-421) |
| Localization |
Cytoplasm |
NGFR
|
Zeta Corporation |
ZM55 |
7 ml |
Ready-to-use |
CE/IVD |
Z2365MP |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM55 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Breast tissue. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant human p75 NGFR protein fragment (around aa 281-421) |
| Localization |
Cytoplasm |
NGFR
|
Zeta Corporation |
ZM55 |
0.5 ml |
Concentrate |
CE/IVD |
Z2365MS |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM55 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Breast tissue. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant human p75 NGFR protein fragment (around aa 281-421) |
| Localization |
Cytoplasm |
NGFR
|
Zeta Corporation |
ZM55 |
0.1 ml |
Concentrate |
CE/IVD |
Z2365MT |
-
|
| Host |
Mouse |
| Clone |
DBM15.15 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Ewing's Sarcoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG2b k |
| Immunogen |
Human full-length recombinant NKX2.2 protein |
| Localization |
Nucleus |
NKX2.2
|
Diagnostic Biosystems |
DBM15.15 |
1 ml |
Concentrate |
CE/IVD |
MOB486 |
-
|
| Host |
Mouse |
| Clone |
DBM15.15 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Ewing's Sarcoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG2b k |
| Immunogen |
Human full-length recombinant NKX2.2 protein |
| Localization |
Nucleus |
NKX2.2
|
Diagnostic Biosystems |
DBM15.15 |
0.1 ml |
Concentrate |
CE/IVD |
MOB486-01 |
-
|
| Host |
Mouse |
| Clone |
DBM15.15 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Ewing's Sarcoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG2b k |
| Immunogen |
Human full-length recombinant NKX2.2 protein |
| Localization |
Nucleus |
NKX2.2
|
Diagnostic Biosystems |
DBM15.15 |
0.5 ml |
Concentrate |
CE/IVD |
MOB486-05 |
-
|
| Host |
Mouse |
| Clone |
DBM15.15 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Ewing's Sarcoma |
| Dilution |
- |
| Isotype |
Mouse IgG2b k |
| Immunogen |
Human full-length recombinant NKX2.2 protein |
| Localization |
Nucleus |
NKX2.2
|
Diagnostic Biosystems |
DBM15.15 |
6 ml |
Ready-to-use |
CE/IVD |
PDM199 |
-
|
| Host |
Mouse |
| Clone |
DBM15.15 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Ewing's Sarcoma |
| Dilution |
- |
| Isotype |
Mouse IgG2b k |
| Immunogen |
Human full-length recombinant NKX2.2 protein |
| Localization |
Nucleus |
NKX2.2
|
Diagnostic Biosystems |
DBM15.15 |
25 ml |
Ready-to-use |
CE/IVD |
PDM199-25 |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM14 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Ewing's sarcoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human recombinant NKX2.2 protein fragment (aa1-119) |
| Localization |
Nucleus |
NKX2.2
|
Zeta Corporation |
ZM14 |
1 ml |
Concentrate |
CE/IVD |
Z2348ML |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM14 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Ewing's sarcoma. |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
Human recombinant NKX2.2 protein fragment (aa1-119) |
| Localization |
Nucleus |
NKX2.2
|
Zeta Corporation |
ZM14 |
7 ml |
Ready-to-use |
CE/IVD |
Z2348MP |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM14 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Ewing's sarcoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human recombinant NKX2.2 protein fragment (aa1-119) |
| Localization |
Nucleus |
NKX2.2
|
Zeta Corporation |
ZM14 |
0.5 ml |
Concentrate |
CE/IVD |
Z2348MS |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM14 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Ewing's sarcoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human recombinant NKX2.2 protein fragment (aa1-119) |
| Localization |
Nucleus |
NKX2.2
|
Zeta Corporation |
ZM14 |
0.1 ml |
Concentrate |
CE/IVD |
Z2348MT |
-
|
| Host |
Rabbit |
| Clone |
D2Y1A |
| Format |
concentrate |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Prostate cancer |
| Dilution |
1:100 |
| Isotype |
IgG |
| Localization |
Nucleus |
NKX3.1
|
Biocare Medical |
D2Y1A |
0.1 ml |
concentrate |
CE/IVD |
ACI3260A |
-
|
| Host |
Rabbit |
| Clone |
D2Y1A |
| Format |
concentrate |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Prostate cancer |
| Dilution |
1:100 |
| Isotype |
IgG |
| Localization |
Nucleus |
NKX3.1
|
Biocare Medical |
D2Y1A |
0.5 ml |
concentrate |
CE/IVD |
ACI3260B |
-
|
| Host |
Rabbit |
| Clone |
D2Y1A |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
CC1 |
| Positive control |
Prostate cancer |
| Dilution |
- |
| Isotype |
IgG |
| Localization |
Nucleus |
NKX3.1
|
Biocare Medical |
D2Y1A |
7 ml |
Ready-to-use |
CE/IVD |
ALI3260G7 |
-
|
| Host |
Rabbit |
| Clone |
D2Y1A |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Prostate cancer |
| Dilution |
- |
| Isotype |
IgG |
| Localization |
Nucleus |
NKX3.1
|
Biocare Medical |
D2Y1A |
6 ml |
Ready-to-use |
CE/IVD |
API3260AA |
-
|
| Host |
Rabbit |
| Clone |
D2Y1A |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
CC1 |
| Positive control |
Prostate cancer |
| Dilution |
- |
| Isotype |
IgG |
| Localization |
Nucleus |
NKX3.1
|
Biocare Medical |
D2Y1A |
6 ml |
Ready-to-use |
CE/IVD |
AVI3260G |
-
|
| Host |
Mouse |
| Clone |
361 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Prostate carcinoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 kappa |
| Immunogen |
Recombinant His fusion protein corresponding to full length human NKX3.1 |
| Localization |
Nuclear |
NKX3.1
|
Diagnostic Biosystems |
361 |
1 ml |
Concentrate |
CE/IVD |
MOB569 |
-
|
| Host |
Mouse |
| Clone |
361 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Prostate carcinoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 kappa |
| Immunogen |
Recombinant His fusion protein corresponding to full length human NKX3.1 |
| Localization |
Nuclear |
NKX3.1
|
Diagnostic Biosystems |
361 |
0.1 ml |
Concentrate |
CE/IVD |
MOB569-01 |
-
|
| Host |
Mouse |
| Clone |
361 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Prostate carcinoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 kappa |
| Immunogen |
Recombinant His fusion protein corresponding to full length human NKX3.1 |
| Localization |
Nuclear |
NKX3.1
|
Diagnostic Biosystems |
361 |
0.5 ml |
Concentrate |
CE/IVD |
MOB569-05 |
-
|
| Host |
Mouse |
| Clone |
361 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Prostate carcinoma |
| Dilution |
- |
| Isotype |
Mouse IgG1 kappa |
| Immunogen |
Recombinant His fusion protein corresponding to full length human NKX3.1 |
| Localization |
Nuclear |
NKX3.1
|
Diagnostic Biosystems |
361 |
6 ml |
Ready-to-use |
CE/IVD |
PDM569 |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM95 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Prostate. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant fragment (around aa 92-224) of human NKX3.1 protein |
| Localization |
Nucleus |
NKX3.1
|
Zeta Corporation |
ZM95 |
1 ml |
Concentrate |
CE/IVD |
Z2395ML |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM95 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Prostate. |
| Dilution |
- |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant fragment (around aa 92-224) of human NKX3.1 protein |
| Localization |
Nucleus |
NKX3.1
|
Zeta Corporation |
ZM95 |
7 ml |
Ready-to-use |
CE/IVD |
Z2395MP |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM95 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Prostate. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant fragment (around aa 92-224) of human NKX3.1 protein |
| Localization |
Nucleus |
NKX3.1
|
Zeta Corporation |
ZM95 |
0.5 ml |
Concentrate |
CE/IVD |
Z2395MS |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM95 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Prostate. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant fragment (around aa 92-224) of human NKX3.1 protein |
| Localization |
Nucleus |
NKX3.1
|
Zeta Corporation |
ZM95 |
0.1 ml |
Concentrate |
CE/IVD |
Z2395MT |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Placenta |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to aa 569-588 of human Nrf2 protein. |
| Localization |
Nuclear, Cytoplasmic |
Nrf2 (TCF11)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
514-12504 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Reactivity |
BV, CH, DG, MS, RB, RT |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Pancreas |
| Dilution |
1:300 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide derived from C-terminal of human NSE. |
| Localization |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
514-3302 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Reactivity |
BV, CH, DG, MS, RB, RT |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Pancreas |
| Dilution |
1:300 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide derived from C-terminal of human NSE. |
| Localization |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
514-3304 |
-
|
| Host |
Mouse |
| Clone |
DBMM4.507 |
| Format |
Concentrate |
| Method |
P |
| Positive control |
Pancreas, Cerebellum, or Pheochromocytoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
IgG2b/kappa |
| Localization |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
DBMM4.507 |
1 ml |
Concentrate |
CE/IVD |
MOB616 |
-
|
| Host |
Mouse |
| Clone |
DBMM4.507 |
| Format |
Concentrate |
| Method |
P |
| Positive control |
Pancreas, Cerebellum, or Pheochromocytoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
IgG2b/kappa |
| Localization |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
DBMM4.507 |
0.1 ml |
Concentrate |
CE/IVD |
MOB616-01 |
-
|
| Host |
Mouse |
| Clone |
DBMM4.507 |
| Format |
Concentrate |
| Method |
P |
| Positive control |
Pancreas, Cerebellum, or Pheochromocytoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
IgG2b/kappa |
| Localization |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
DBMM4.507 |
0.5 ml |
Concentrate |
CE/IVD |
MOB616-05 |
-
|
| Host |
Mouse |
| Clone |
DBMM4.507 |
| Format |
ready-to-use |
| Method |
P |
| Positive control |
Pancreas, Cerebellum, or Pheochromocytoma |
| Dilution |
--- |
| Isotype |
IgG2b/kappa |
| Localization |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
DBMM4.507 |
6 ml |
ready-to-use |
CE/IVD |
PDM616 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Method |
F, P |
| Positive control |
Pancreas |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR006 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Pancreas |
| Dilution |
1:25 - 1:50 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP054 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Pancreas |
| Dilution |
1:25 - 1:50 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP054-01 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Pancreas |
| Dilution |
1:25 - 1:50 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP054-05 |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM24 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Pancreas or brain. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
A synthetic peptide corresponding to aa416-433 of human NSE gamma |
| Localization |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zeta Corporation |
ZM24 |
1 ml |
Concentrate |
CE/IVD |
Z2351ML |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM24 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Pancreas or brain. |
| Dilution |
- |
| Isotype |
IgG2b /κ |
| Immunogen |
A synthetic peptide corresponding to aa416-433 of human NSE gamma |
| Localization |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zeta Corporation |
ZM24 |
7 ml |
Ready-to-use |
CE/IVD |
Z2351MP |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM24 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Pancreas or brain. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
A synthetic peptide corresponding to aa416-433 of human NSE gamma |
| Localization |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zeta Corporation |
ZM24 |
0.5 ml |
Concentrate |
CE/IVD |
Z2351MS |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM24 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Pancreas or brain. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
A synthetic peptide corresponding to aa416-433 of human NSE gamma |
| Localization |
Cytoplasm |
NSE (Neuron Specific Enolase)
|
Zeta Corporation |
ZM24 |
0.1 ml |
Concentrate |
CE/IVD |
Z2351MT |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM82 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Tonsil. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant human NPM1 protein fragment (aa185-287) |
| Localization |
Nucleoli. |
Nucleophosmin (NPM1)
|
Zeta Corporation |
ZM82 |
1 ml |
Concentrate |
CE/IVD |
Z2405ML |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM82 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Tonsil. |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant human NPM1 protein fragment (aa185-287) |
| Localization |
Nucleoli. |
Nucleophosmin (NPM1)
|
Zeta Corporation |
ZM82 |
7 ml |
Ready-to-use |
CE/IVD |
Z2405MP |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM82 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Tonsil. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant human NPM1 protein fragment (aa185-287) |
| Localization |
Nucleoli. |
Nucleophosmin (NPM1)
|
Zeta Corporation |
ZM82 |
0.5 ml |
Concentrate |
CE/IVD |
Z2405MS |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM82 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Tonsil. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant human NPM1 protein fragment (aa185-287) |
| Localization |
Nucleoli. |
Nucleophosmin (NPM1)
|
Zeta Corporation |
ZM82 |
0.1 ml |
Concentrate |
CE/IVD |
Z2405MT |
-
|
|
Nuclear Protein in Testis |
| Host |
Rabbit |
| Clone |
ZR456 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
NUT carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
A peptide corresponding to human NUT proteinund aa1-100) of human Claudin18.2 protein |
| Localization |
Nucleus |
NUT
|
Zeta Corporation |
ZR456 |
1 ml |
Concentrate |
RUO |
Z2810RL-R |
-
|
| Host |
Rabbit |
| Clone |
DBRRM7.36 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Testis |
| Dilution |
1:50-1:100 |
| Isotype |
IgG kappa |
| Immunogen |
Recombinant human NUT1 protein fragment (around aa 900-1100) |
| Localization |
Nuclear, Cytoplasmic |
NUT1
|
Diagnostic Biosystems |
DBRRM7.36 |
1 ml |
Concentrate |
Übergangsfrist |
RMAB115R |
-
|
| Host |
Rabbit |
| Clone |
DBRRM7.36 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Testis |
| Dilution |
1:50-1:100 |
| Isotype |
IgG kappa |
| Immunogen |
Recombinant human NUT1 protein fragment (around aa 900-1100) |
| Localization |
Nuclear, Cytoplasmic |
NUT1
|
Diagnostic Biosystems |
DBRRM7.36 |
0.1 ml |
Concentrate |
Übergangsfrist |
RMAB115R-01 |
-
|
| Host |
Rabbit |
| Clone |
DBRRM7.36 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Testis |
| Dilution |
1:50-1:100 |
| Isotype |
IgG kappa |
| Immunogen |
Recombinant human NUT1 protein fragment (around aa 900-1100) |
| Localization |
Nuclear, Cytoplasmic |
NUT1
|
Diagnostic Biosystems |
DBRRM7.36 |
0.5 ml |
Concentrate |
Übergangsfrist |
RMAB115R-05 |
-
|
| Host |
Rabbit |
| Clone |
DBRRM7.36 |
| Format |
ready-to-use |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Testis |
| Dilution |
--- |
| Isotype |
IgG kappa |
| Immunogen |
Recombinant human NUT1 protein fragment (around aa 900-1100) |
| Localization |
Nuclear, Cytoplasmic |
NUT1
|
Diagnostic Biosystems |
DBRRM7.36 |
6 ml |
ready-to-use |
Übergangsfrist |
RMPD115R |
-
|
| Host |
Rabbit |
| Clone |
ZR227 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
B-cell lymphoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant human OCT2 protein fragment (around aa 112-297) |
| Localization |
Nuclear |
OCT-2
|
Zeta Corporation |
ZR227 |
0.1 ml |
Concentrate |
CE/IVD |
Z2708RT |
-
|